NQ301|cas:130089-98-4|西域试剂

NQ301,98.12%

产品编号：Bellancom-101054| CAS NO：130089-98-4| 分子式：C₁₈H₁₂ClNO₃| 分子量：325.75

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	价格	库存与货期
Bellancom-101054	￥600.00	杭州北京（现货）
Bellancom-101054	￥900.00	杭州北京（现货）
Bellancom-101054	￥1500.00	杭州北京（现货）
Bellancom-101054	￥2500.00	杭州北京（现货）
Bellancom-101054	￥4500.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

NQ301

产品介绍

NQ301是一种抗血栓剂; 可抑制胶原蛋白激发的兔血小板聚集，IC₅₀值为10 mg/mL。

生物活性

NQ301 is an antithrombotic agent; inhibits collagen-challenged rabbit platelet aggregation with an IC₅₀ of 10 mg/mL.

体外研究

NQ301 concentration-dependently inhibits collagen (10 mg/mL)-, U46619 (1 mg/mL)- and arachidonic acid (100 mg/mL)-challenged rabbit platelet aggregation, with IC₅₀ values of 0.60±0.02, 0.58±0.04 and 0.78±0.04 μM, respectively. NQ301 potently suppresses thromboxane B₂ formation by platelets that are exposed to arachidonic acid in a concentration-dependent manner, but had no effect on the production of prostaglandin D₂, indicating an inhibitory effect on thromboxane A₂ synthase. NQ301 has a potential to inhibit thromboxane A₂ synthase activity with thromboxane A₂/prostaglandin H₂ receptor blockade, and modulate arachidonic acid liberation as well as 12-hydroxy-5,8,10,14-eicosatetraenoic acid formation in platelets. NQ301 inhibits platelet aggregation by suppression of the intracellular pathway, rather than by direct inhibition of fibrinogen-GPIIb/IIIa complex binding. NQ301 significantly inhibits the increase of cytosolic Ca²⁺ concentration and ATP secretion, and also significantly increases platelet cAMP levels in the activated platelets. The antiplatelet activity of NQ301 may be mediated by inhibition of cytosolic Ca²⁺ mobilization, enhancement of cAMP production and inhibition of ATP secretion in activated platelets.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究

性状

Solid

溶解性数据

In Vitro:

DMSO : ≥ 7.14 mg/mL (21.92 mM)

* "≥" means soluble, but saturation unknown.

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	3.0698 mL	15.3492 mL	30.6984 mL
5 mM	0.6140 mL	3.0698 mL	6.1397 mL
10 mM	0.3070 mL	1.5349 mL	3.0698 mL

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

1.

请依序添加每种溶剂： 10% DMSO 40% PEG300 5% Tween-80 45% saline
Solubility: 0.71 mg/mL (2.18 mM); Suspended solution; Need ultrasonic

此方案可获得 0.71 mg/mL (2.18 mM) 的均匀悬浊液，悬浊液可用于口服和腹腔注射。
以 1 mL 工作液为例，取 100 μL 7.1 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。
将 0.9 g 氯化钠，完全溶解于 100 mL ddH₂O 中，得到澄清透明的生理盐水溶液